Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DSP107,Atezolizumab

            Therapeutic Area: Oncology Product Name: DSP107

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: aMoon

            Deal Size: $46.5 million Upfront Cash: Undisclosed

            Deal Type: Financing June 16, 2021

            Details:

            Proceeds will enable further clinical development of DSP107, a first-in-class CD47x41BB targeting fusion protein, for the treatment of solid and hematological tumors and accelerate the path towards clinical development of the Company's preclinical pipeline.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): COM701,Nivolumab,BMS-986207

            Therapeutic Area: Oncology Product Name: PVRIG

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 09, 2021

            Details:

            Article highlights include Detailed overview of the DNAM-1 axis including axis checkpoint molecules: DNAM-1, TIGIT, PVRIG and CD96, along with their ligands PVR and PVRL2.